A novel long-term intravenous combined with local treatment with human amnion-derived mesenchymal stem cells for a multidisciplinary rescued uremic calciphylaxis patient and the underlying mechanism
Authors:
Open Access
- 10 February 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 14 (2)
Abstract
Calciphylaxis is a rare disease characterized histologically by microvessel calcification and microthrombosis, with high mortality and no proven therapy. Here, we reported a severe uremic calciphylaxis patient with progressive skin ischemia, large areas of painful malodorous ulcers, and mummified legs. Because of the worsening symptoms and signs refractory to conventional therapies, treatment with human amnion-derived mesenchymal stem cells (hAMSCs) was approved. Preclinical release inspections of hAMSCs, efficacy, and safety assessment, including cytokine secretory ability, immunocompetence, tumorigenicity, and genetics analysis in vitro, were introduced. We further performed acute and long-term hAMSC toxicity evaluations in C57BL/6 mice and rats, abnormal immune response tests in C57BL/6 mice, and tumorigenicity tests in neonatal Balbc-nu nude mice. After the preclinical research, the patient was treated with hAMSCs by intravenous and local intramuscular injection and external supernatant application to the ulcers. When followed up to 15 months, the blood-based markers of bone and mineral metabolism improved, with skin soft tissue regeneration and a more favorable profile of peripheral blood mononuclear cells. Skin biopsy after 1-month treatment showed vascular regeneration with mature noncalcified vessels within the dermis, and 20 months later, the re-epithelialization restored the integrity of the damaged site. No infusion or local treatment-related adverse events occurred. Thus, this novel long-term intravenous combined with local treatment with hAMSCs warrants further investigation as a potential regenerative treatment for uremic calciphylaxis due to effects of inhibiting vascular calcification, stimulating angiogenesis and myogenesis, anti-inflammatory and immune modulation, multidifferentiation, re-epithelialization, and restoration of integrity.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81270408, 81570666, 81730041, 81671447)
- International Society of Nephrology
- Construction Program of Jiangsu Provincial Clinical Research Center Support System (BL2014084)
- Jiangsu Province Key Medical Personnel Project (ZDRCA2016002)
- National Key Research and Development Program of China (2017YFC1001303)
- Program of Jiangsu Province Clinical Medical Center (YXZXB2016001, BL2012009)
This publication has 51 references indexed in Scilit:
- Muscle as a Secretory Organ2013
- Chapter 1: Diagnosis and evaluation of anemia in CKDKidney International Supplements, 2012
- Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cellsCytokine, 2012
- Peripheral Blood FibrocytesAnnals of Surgery, 2011
- Basic and Therapeutic Aspects of AngiogenesisCell, 2011
- VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancerJournal of Experimental Medicine, 2010
- Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties?Molecular Cancer, 2008
- PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healingWound Repair and Regeneration, 2008
- Conventional and molecular cytogenetic diagnostic methods in stem cell research: A concise reviewCell Biology International, 2007
- Interleukin-6 Stimulates Circulating Blood-Derived Endothelial Progenitor Cell Angiogenesis in vitroJournal of Cerebral Blood Flow & Metabolism, 2007